Production (Stage)
MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.28% | 19.27% | 26.62% | 32.77% | 48.31% |
| Total Depreciation and Amortization | -22.85% | 1.95% | 16.82% | 13.71% | 8.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 133.35% | 130.29% | 157.53% | 143.20% | -196.76% |
| Change in Net Operating Assets | -162.38% | -52.65% | -7.69% | -30.31% | -45.35% |
| Cash from Operations | 43.94% | 61.32% | 83.57% | 64.39% | 22.46% |
| Capital Expenditure | 63.73% | 67.94% | 65.66% | 37.24% | 38.28% |
| Sale of Property, Plant, and Equipment | -99.22% | -72.88% | -61.16% | -- | 35,438.18% |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -29.51% | -29.51% | -29.51% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -102.01% | -93.93% | -42.65% | 2.34% | 41.58% |
| Total Debt Issued | -25.12% | -25.12% | -25.12% | -29.80% | -20.43% |
| Total Debt Repaid | -63.38% | -51.72% | -43.88% | 41.33% | -43.35% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -80.98% | -32.12% | -18.23% | -12.95% | 961.07% |
| Cash from Financing | -498.90% | -405.53% | -252.49% | 119.04% | 1,612.92% |
| Foreign Exchange rate Adjustments | 102.60% | 101.58% | -73.61% | -179.00% | -224.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -148.24% | 0.53% | 102.19% | 116.39% | 61.56% |